Biotechnology
Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. The company's product candidates are DYNE-101 and DYNE-251, both arein the ongoing phase 1/2 clinical trial.

$2.5B

Market Cap • 12/26/2024

2017

(7 years)
Founded

2020

(4 years ago)
IPO

NASDAQ

Listing Exchange
Flag of US

Waltham

Headquarters • Massachusetts